earn includ top- vs bottom- line vs
beat manag increas guidanc reflect
on-going rapid uptak symdeko ph tripl trial set complet enrol
nda expect industry-lead top-lin growth
thru remain top pick
vertex report financi includ q/q y/i cystic fibrosi
cf franchis revenu beat consensu consist
q/q y/i kalydeco sale q/q y/i
orkambi symdeko first full quarter market
manag note meaning channel build revenu
growth driven patient demand symdeko rapid uptak basi vertex
increas sale guidanc guidanc
assum addit fund agreement secur ex-u though convers
regul addit countri continu
vertex report gross margin vs non-gaap sg
expens respect total vs
non-gaap net incom per share basi well ahead
consensu guidanc combin sg expens
non- basi reiter
combin sale symdeko orkambi
q/q compar orkambi symdeko sale therefor
even take account symdeko price premium orkambi symdeko launch
rapidli grown market franchis tonight call manag indic
symdeko uptak strongest among patient never initi treatment
previous discontinu therapi patient switch
orkambi kalydeco symdeko also contribut level market expans
consult expect physician survey advanc march
confer believ symdeko launch would increas use
corrector/potenti therapi symdeko exceed level growth alreadi
indic full market penetr yet reach unlik
reach nonetheless revis financi guidanc impli
futur market growth somewhat slower pace bottom end
guidanc nearli reach addit q/q growth cf franchis revenu
top-end impli approx q/q compound-annual-growth-rate
pleas see page report import disclosur
cftr potenti kalydeco standard care cf patient gate partial loss
function mutat also develop regimen contain kalydeco cftr
corrector lumacaftor tezacaftor potenti address cf patient
harbor least one allel orkambi lumacaftor kalydeco approv
juli symdeko tezacaftor kalydeco februari tripl combin
contain gener corrector well tezacaftor ivacaftor produc impress
ph ii data regimen enter pivot develop fda file
anticip tripl regimen appear repres true breakthrough
treatment improv qualiti life extend life span patient
model assum cystic fibrosi patient one vertex therapi
drive franchis sale dcf-base price target
complet enrol ph trial
tez/iva
initi phase develop
b-thal scd
final phase i/ii plan
cystic fibrosi patient
one vertex therapi
drive franchis sale
franchis maintain exclus
earli
cystic
fibrosi patient one vertex
therapi drive
franchis sale
fewer cystic
fibrosi patient one vertex
therapi drive less
franchis sale
franchis maintain exclus
vertex face meaning competit
rest pipelin contribut
past earli
anoth vertex pipelin program
vertex leader treatment cystic fibrosi orkambi kalydeco standard
therapi cystic fibrosi patient homozyg mutat
rate residu function mutat vertex gener posit proof-of-concept
data multipl tripl combin regimen incorpor second gener corrector
patient tripl regimen appear
repres true breakthrough treatment improv qualiti life extend
life span cystic fibrosi world-wide moreov patent protect
least earli vertex franchis long commerci life early-stag
pipelin includ candid osteoarthr adrenoleukodystrophi antitrypsin
defici sickl cell diseas polycyst kidney diseas first expect
enter clinic develop
vertex advanc two second gener corrector phase develop
combin tezacaftor ivacaftor phase program consist trial
vertex initi phase trial tez/iva /- homozygot
phase trial tez/iva vs placebo het min patient june
vertex began tez/iva vs placebo het min patient clinicaltri gov
list ph studi tez/iva /- homozygot yet recruit
juli expect start date
tonight call manag indic enrol phase triplet trial set
complet nda submiss chosen regimen plan
latest think phase ii data larg de-risk phase data
date kalydeco orkambi symdeko tripl regimen suggest short term
efficaci safeti indic long-term profil cftr-direct regimen
therefor think littl risk current phase iii could fail moreov given
dramat effect lung function produc phase ii think shorter phase
iii provid physician suffici inform regimen adopt
fda file track launch seem like today increas
cf franchis revenu estim reflect triplet sale
year
vertex busi continu hum good short- long- term prospect symdeko
launch drove impress top- bottom- line beat well increas guidanc
 market yet fulli penetr prospect growth futur quarter
good even somewhat slower pace importantli vertex long-term growth
prospect similarli strong read-out glpg pelican data june investor
concern competit glpg/abbv near- intermediate-term
lessen meanwhil tripl regimen continu make steadi progress
phase program finish enrol expect launch
first tripl regimen produc dramat improv lunch function
like extend life expect tripl rapidli broadli adopt base
promis tripl regimen project revenu
compound-annual-growth-rate ep compound-annual-growth-rate highest larg cap biotech base prospect
strong long-term growth remain top larg cap pick dcf-base price
target
vertex leader discoveri develop candid treat cystic
fibrosi vertex first cystic fibrosi commerci product kalydeco ivacaftor
in-class cftr potenti compound kalydeco approv fda januari
patient gate mutat mutat
addit residu function mutat subsequ ad label seri
supplement approv estim kalydeco achiev
world-wide sale patient gate defect
partial loss function cftr mutat vertex also develop regimen contain
kalydeco cftr corrector lumacaftor tezacaftor potenti address
cf patient harbor least one allel orkambi lumacaftor ivacaftor
succeed two pivot trial june approv juli
symdeko tezacaftor ivacaftor produc posit data two phase trial
march fda approv februari expect licensur follow
europ expect orkambi symdeko wide adopt
cystic fibrosi patient homozyg mutat world-wide
improv potenc orkambi symdeko homozygot
effect patient one copi allel vertex advanc
second gener corrector clinic develop act synergist
lumacaftor tezacaftor complet correct fold defect
cftr tripl combin contain tezacaftor ivacaftor four second
gener corrector produc impress phase ii proof-of-concept data
tripl regimen result mean absolut improv percentag
point percentag point patient four tripl regimen
well toler base proof-of-concept data vertex move two once-
daili second gener corrector phase
homozyg heterozyg patient vertex expect file fda approv
tripl regimen heterozyg patient impli launch
tripl regimen appear repres true breakthrough treatment
improv qualiti life extend life span patient
cystic fibrosi world-wide moreov second gener corrector patent
protect least earli vertex franchis long
commerci life model assum cystic fibrosi patient one
vertex therapi drive franchis sale dcf-base price target
ema approv symdeko combin
initi phase trial iv formul
complet enrol phase trial tripl combin regimen cf
final ph i/ii plan
obtain addit ex-u reimburs orkambi homozygot patient
partner crispr initi phase i/ii trial -thalassemia europ
initi phase trial sickl cell diseas
possibl updat merck kgaa oncolog
possibl in-licens partnership extern pipelin asset
advanc addit next-gener corrector develop
advanc addit non-cf pipelin candid clinic
phase ii data inhibitor small fiber neuropathi
partner releas phase data pimodivir influenza non-hospit patient
result pivot trial tripl combin regimen homozyg het
file fda approv first tripl regimen
partner releas phase data pimodivir influenza hospit patient
cowen compani
cowen compani
statesnumb patient diagnos patient penetr patient per patient patient gate gate penetr patient per patient patient gate mutat homozyg homozyg regimen penetr patient vertex per patient patient heterozyg heterozyg regimen penetr patient vertex per patient hetero patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu patient diagnos patient penetr patient per patient gate gate penetr patient per patient patient gate homozyg regimen penetr patient vertex per patient heterozyg heterozyg regimen penetr patient vertex per patient hetero row patient vertex kalydeco orkambi/symdeko/tripl cystic fibrosi revenu kalydeco kalydeco orkambi orkambi/symdeko/tripl cystic fibrosi patient vertex cystic fibrosi cowen
cowen compani
fy dec except per symdeko tripl growth expensesroyalti good product develop ex gener administr ex base cost loss incom rate incom loss attribut non-controlling lncome exclud soe exclud soe expens net share share stock option expens cowen
cowen compani
fy dec except per cagrrevenu kalydeco symdeko tripl growth expensesroyalti good product develop ex gener administr ex cost incometot loss incom rate lncome exclud soe exclud soe expens net share cowen
cowen compani
financi year incivek cystic fibrosi payment tax asset ratetot unus tax free year growth ratetermin valu termin valu net per valu calcul cowen
calcul target price employ one valuat methodolog
includ discount earn analysi discount cash flow analysi net present
valu analysi and/or compar compani analysi analys may may
requir use object measur price-to-earn price-to-sal multipl
well subject measur discount rate
make invest recommend earli stage pre-commerci biotechnolog
compani base upon assess technolog probabl pipelin
success potenti market opportun event success howev
compani lack tradit financi metric believ good
methodolog assign specif target price stock
multipl risk inher invest biotechnolog sector
beyond system risk also clinic regulatori commerci risk addit
biotechnolog compani requir signific amount capit order develop
clinic program capital-rais environ alway chang risk
necessari capit complet develop may readili avail
vertex deriv great major revenu two relat product kalydeco
orkambi forecast sale franchis difficult outlook could
alter new safety/efficaci find emerg competit alter medic
treatment paradigm chang pricing/reimburs environ vertex
stock price could also affect chang outlook key pipelin program
includ second gener corrector evalu market potenti
drug yet approv particularli riski
